Abstracts tagged "decision analysis and systemic lupus erythematosus (SLE)"

Abstract Number: 1589 • 2017 ACR/ARHP Annual Meeting
A Multicriteria Decision Analysis for the Development of New Systemic Lupus Erythematosus Classification Criteria
Sara K. Tedeschi¹, Sindhu Johnson², Dimitrios Boumpas³, David I. Daikh⁴, Betty Diamond⁵, Thomas Doerner⁶, Søren Jacobsen⁷, Diane L. Kamen⁸, W. Joseph McCune⁹, Marta Mosca¹⁰, Rosalind Ramsey-Goldman¹¹, Guillermo Ruiz-Irastorza¹², Matthias Schneider¹³, Josef S. Smolen¹⁴, Murray Urowitz¹⁵, David Wofsy¹⁶, Martin Aringer¹⁷, Raymond P. Naden¹⁸ and Karen H. Costenbader^19,20, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ³University of Athens, Athens, Greece, ⁴Rheumatology, UCSF/VA Medical Center, San Francisco, CA, ⁵Feinstein Institute for Medical Research, Manhasset, NY, ⁶Charité Universitätmedizin Berlin and DRFZ, Berlin, Germany, ⁷Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁸Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁹Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ¹⁰Rheumatology Unit, University of Pisa, Pisa, Italy, ¹¹FSM, Northwestern University, Chicago, IL, ¹²Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Baracaldo, Spain, ¹³Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ¹⁴Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹⁵Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Rheumatology, UCSF, San Francisco, CA, ¹⁷Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ¹⁸New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ¹⁹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²⁰Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA
Background/Purpose: EULAR and ACR are supporting multi-phase development of SLE classification criteria based on weighted criteria and a continuous probability scale. Prior steps included criteria…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].